Ultime notizie per scPharmaceuticals (NASDAQ:SCPH) Azioni

scPharmaceuticals

scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.

scPharmaceuticals Inc

WIIM

ACHR

Archer Aviation shares are trading higher after the company reported better-than-expected Q3 EPS results.

Barclays analyst Adrienne Yih maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Overweight and raises the price target from $200 to $257.

News

Price Target

Analyst Ratings

Barclays Maintains Overweight on Ralph Lauren, Raises Price Target to $257

ESPR

Esperion Therapeutics shares are trading higher. The stock may be moving on continued strength after reporting better-than-expected Q3 financing results yesterday. Also, HC Wainwright & Co. reiterated a Buy rating on the stock.

Over the past 24 hours, dogwifhat's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>) price has fallen 3.22% to $2.31. This is opposite to its positive trend over the past week where it has experienced a 2.0% gain, moving from $2.25 to its current price. 
The chart below compares the price movement and volatility for dogwifhat over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1731092476_0.png" alt="price_chart" />
The trading volume for the coin has increased 63.0% over the past week. while the overall circulating supply of the coin has decreased 0.21% This puts its current circulating supply at an estimated 100.0% of its max supply, which is 998.93 million. The current market cap ranking for WIF is #48 at $2.31 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1731092477_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Movers

Trading Ideas

$WIF

Cryptocurrency dogwifhat Down More Than 3% Within 24 hours

Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) reported better-than-expected third-quarter adjusted EPS <a href="https://www.benzinga.com/quote/EXPE/earnings">results on Thursday</a>.
Expedia Group reported quarterly earnings of $6.13 per share which beat the analyst consensus estimate of $6.04 per share. The company reported quarterly sales of $4.06 billion which missed the analyst consensus estimate of $4.11 billion.
&#8220;Our third quarter results exceeded our expectations on gross bookings and earnings with revenue landing in-line. We accelerated bookings growth in our consumer business for the second consecutive quarter, and our advertising and B2B businesses continue to deliver strong double-digit growth,&#8221; said Ariane Gorin, CEO of Expedia Group.
Expedia shares gained 4.8% to trade at $182.45 on Friday.
These analysts made changes to their price targets on Expedia following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d3cdb7b85e930001808a59/daniel-kurnos">Benchmark analyst Daniel Kurnos</a> maintained Expedia with a Buy and raised the price target from $180 to $200.</li>
<li>Wedbush analyst Scott Devitt maintained the stock with a Neutral and raised the price target from $130 to $180.</li>
<li>Oppenheimer analyst Jed Kelly maintained the stock with an Outperform and raised the price target from $155 to $210.</li>
<li>JP Morgan analyst Doug Anmuth maintained Expedia Group with a Neutral and raised the price target from $135 to $170.</li>
<li>BTIG analyst Jake Fuller maintained the stock with a Buy and boosted the price target from $175 to $200.</li>
<li>Barclays analyst Trevor Young maintained Expedia with an Equal-Weight and raised the price target from $134 to $153.</li>
</ul>
Considering buying EXPE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="566" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135943/image-94-1024x566.png" alt="" class="wp-image-638359" style="width:534px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135943/image-94-1024x566.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135943/image-94-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135943/image-94-768x425.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135943/image-94.png 1188w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Earnings

EXPE

Expedia Analysts Boost Their Forecasts Following Better-Than-Expected Earnings

Needham analyst Chris Pierce maintains ACV Auctions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NASDAQ">ACVA</a>) with a Buy and raises the price target from $23 to $26.

ACVA

Needham Maintains Buy on ACV Auctions, Raises Price Target to $26

During the last three months, 10 analysts shared their evaluations of First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated First Horizon and provided 12-month price targets. The average target is $19.75, accompanied by a high estimate of $23.00 and a low estimate of $17.00. Witnessing a positive shift, the current average has risen by 3.4% from the previous average price target of $19.10.
<img src="https://www.benzinga.com/files/images/story/2024/1731092460_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive First Horizon. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Michael Rose</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Russell Gunther</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$18.50</td>
<td>$19.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to First Horizon. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of First Horizon compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for First Horizon's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into First Horizon's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FHN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on First Horizon analyst ratings.</a>
<h2>Unveiling the Story Behind First Horizon</h2>
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The regional bank is responsible for roughly 65% of its revenue, while capital markets make a 25% contribution. The remainder is split between the firm's non-strategic (wind-down) and corporate operations. First Horizon concentrates on offering a variety of banking products mainly in its home state, where it has the second- largest deposit franchise with a 13% deposit market share.
<h3>A Deep Dive into First Horizon's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: First Horizon displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 4.42%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: First Horizon's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 25.76%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.53%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): First Horizon's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.26%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.22, First Horizon adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 10 Analyst Recommendations For First Horizon

In the preceding three months, 4 analysts have released ratings for Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $13.38, a high estimate of $16.00, and a low estimate of $10.50. Marking an increase of 13.87%, the current average surpasses the previous average price target of $11.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1731092452_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Funko is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Drew Crum</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.50</td>
<td>$9.00</td>
</tr>
<tr>
<td>Eric Wold</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Funko. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Funko compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Funko's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FNKO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Funko analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Funko</h2>
Funko Inc is an us-based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
<h3>Understanding the Numbers: Funko's Finances</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Funko's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 3.18%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Funko's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.07%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Funko's ROE stands out, surpassing industry averages. With an impressive ROE of 2.35%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Funko's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.7% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Funko's debt-to-equity ratio surpasses industry norms, standing at 1.37. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FNKO

Breaking Down Funko: 4 Analysts Share Their Views

Analysts' ratings for BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) over the last quarter vary from bullish to bearish, as provided by 17 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, a high estimate of $150.00, and a low estimate of $91.00. This upward trend is apparent, with the current average reflecting a 19.85% increase from the previous average price target of $106.41.
<img src="https://www.benzinga.com/files/images/story/2024/1731092443_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of BioNTech by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$122.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$122.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$124.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Yifeng Liu</td>
<td>HSBC</td>
<td>Raises</td>
<td>Buy</td>
<td>$136.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Emmanuel Papadakis</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$131.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$96.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$91.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to BioNTech. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BioNTech compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for BioNTech's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of BioNTech's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BNTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on BioNTech analyst ratings.</a>
<h2>Discovering BioNTech: A Closer Look</h2>
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
<h3>BioNTech's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining BioNTech's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 39.04% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: BioNTech's net margin excels beyond industry benchmarks, reaching 15.91%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): BioNTech's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.04% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): BioNTech's ROA stands out, surpassing industry averages. With an impressive ROA of 0.89%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BNTX

What Analysts Are Saying About BioNTech Stock

Galiano Gold shares are trading lower after the company reported worse-than-expected Q3 revenue results.

In the last three months, 13 analysts have published ratings on Permian Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Permian Resources and provided 12-month price targets. The average target is $18.38, accompanied by a high estimate of $21.00 and a low estimate of $14.00. Highlighting a 6.94% decrease, the current average has fallen from the previous average price target of $19.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1731092433_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Permian Resources among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Subash Chandra</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Hanwen Chang</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$19.00</td>
<td>-</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Permian Resources. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Permian Resources compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Permian Resources's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Permian Resources's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Permian Resources analyst ratings.</a>
<h2>About Permian Resources</h2>
Permian Resources Corp is an independent oil and natural gas company focused on generating outsized returns to stakeholders through the responsible acquisition, optimization and development of oil and liquids-rich natural gas assets. The Company's assets and operations are primarily concentrated in the core of the Permian Basin, and its properties consist of large, contiguous acreage blocks located in West Texas and New Mexico.
<h3>Permian Resources's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Permian Resources's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -2.45%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: Permian Resources's net margin excels beyond industry benchmarks, reaching 31.79%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Permian Resources's ROE stands out, surpassing industry averages. With an impressive ROE of 4.46%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Permian Resources's ROA stands out, surpassing industry averages. With an impressive ROA of 2.41%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Permian Resources's debt-to-equity ratio is below the industry average. With a ratio of 0.48, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Permian Resources

Freeport-McMoRan's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) short percent of float has risen 6.87% since its last report. The company recently reported that it has 24.41 million shares sold short, which is 1.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.45 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Freeport-McMoRan Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731092422_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Freeport-McMoRan has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Freeport-McMoRan's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Freeport-McMoRan's peer group average for short interest as a percentage of float is 3.66%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(FCX) - Analyzing Freeport-McMoRan's Short Interest

In the last three months, 13 analysts have published ratings on Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $46.69, a high estimate of $52.00, and a low estimate of $36.00. This current average has increased by 7.23% from the previous average price target of $43.54. 
<img src="https://www.benzinga.com/files/images/story/2024/1731092421_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Cheesecake Factory's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nick Setyan</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Katherine Griffin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$49.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$44.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>David Tarantino</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Nick Setyan</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Dennis Geiger</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$36.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Katherine Griffin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Nick Setyan</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jon Tower</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Cheesecake Factory. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cheesecake Factory compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Cheesecake Factory's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Cheesecake Factory's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CAKE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cheesecake Factory analyst ratings.</a>
<h2>Discovering Cheesecake Factory: A Closer Look</h2>
Cheesecake Factory Inc owns and operates restaurants in the United States and Canada under brands that include The Cheesecake Factory, North Italia, and a collection within the Fox Restaurants Concepts subsidiary. The company's international presence, in the Middle East and Mexico, is through licensing agreements with third parties. The company also has a bakery division that produces cheesecakes and other baked products for sale in its restaurants, international licensees, and third-party bakery customers. The company has four operating business segments: The Cheesecake Factory restaurants, North Italia, other FRC, and Flower Child. Majority of the company's revenue comes from The Cheesecake Factory restaurants segment.
<h3>Understanding the Numbers: Cheesecake Factory's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Cheesecake Factory's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 4.25%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Cheesecake Factory's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 3.47%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 7.79%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Cheesecake Factory's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.03%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Cheesecake Factory's debt-to-equity ratio is below the industry average. With a ratio of 4.76, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAKE

What Analysts Are Saying About Cheesecake Factory Stock

Ulta Beauty's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NYSE">ULTA</a>) short percent of float has fallen 10.65% since its last report. The company recently reported that it has 2.06 million shares sold short, which is 5.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.02 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ulta Beauty Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731092417_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ulta Beauty has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ulta Beauty's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ulta Beauty's peer group average for short interest as a percentage of float is 12.81%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ULTA

Looking Into Ulta Beauty's Recent Short Interest

5 analysts have shared their evaluations of Coeur Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDE#NYSE">CDE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $7.95, with a high estimate of $8.50 and a low estimate of $7.00. This upward trend is evident, with the current average reflecting a 5.3% increase from the previous average price target of $7.55.
<img src="https://www.benzinga.com/files/images/story/2024/1731092412_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Coeur Mining. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Reagor</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.50</td>
<td>$9.00</td>
</tr>
<tr>
<td>Dalton Baretto</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$7.75</td>
<td>$7.00</td>
</tr>
<tr>
<td>Joe Reagor</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$8.50</td>
<td>$8.00</td>
</tr>
<tr>
<td>Kevin O'Halloran</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$8.00</td>
<td>$7.50</td>
</tr>
<tr>
<td>Brian MacArthur</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$7.00</td>
<td>$6.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Coeur Mining. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Coeur Mining compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Coeur Mining's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Coeur Mining's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CDE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Coeur Mining analyst ratings.</a>
<h2>Discovering Coeur Mining: A Closer Look</h2>
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada Mexico, and North America.
<h3>Financial Milestones: Coeur Mining's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Coeur Mining's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 61.1% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Coeur Mining's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 15.55%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.61%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.23%, the company showcases effective utilization of assets.
Debt Management: Coeur Mining's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.56, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Coeur Mining Stock: Analyst Perspectives (5 Ratings)

Welltower's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) short percent of float has fallen 22.32% since its last report. The company recently reported that it has 8.59 million shares sold short, which is 1.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Welltower Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731092411_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Welltower has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Welltower's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Welltower's peer group average for short interest as a percentage of float is 7.34%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

WELL

Looking Into Welltower's Recent Short Interest

Over the past 24 hours, Bittensor's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TAO</a>) price has fallen 3.49% to $496.14. This is opposite to its positive trend over the past week where it has experienced a 7.0% gain, moving from $458.76 to its current price. 
The chart below compares the price movement and volatility for Bittensor over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1731092406_0.png" alt="price_chart" />
Bittensor's trading volume has climbed 10.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has increased 0.08%. This brings the circulating supply to 7.38 million, which makes up an estimated 35.15% of its max supply of 21.00 million. According to our data, the current market cap ranking for TAO is #31 at $3.66 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1731092406_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$TAO

Cryptocurrency Bittensor Decreases More Than 3% Within 24 hours

<a href="https://x.com/IcebergResear/status/1854961131745690053">https://x.com/IcebergResear/status/1854961131745690053</a>
We are short Gevo Inc ($GEVO). The change in the US administration is the obvious threat but problems run deeper, in particular the competitiveness of technology. A lot of room to fall further.
In its last days, the Biden-driven Department of Energy has granted conditional approval for a $1.46b loan to Gevo, aimed at building a plant to produce alcohol-to-jet ("ATJ") aviation fuel.
Under a Trump-led administration, who called the IRA a "Green New Scam", Gevo's project is one of the most vulnerable DOE conditional approvals. The massive loan is subject to multiple conditions before approval, placing control in the hands of the DOE's new leadership.
Sustainable aviation fuels (SAF), whether HEFA or ATJ, are structurally more expensive than traditional jet fuel, and rely heavily on tax credits e.g. IRA and RFS. Generous IRA credits are now threatened and in any case, they expire in 2027.
ATJ (Gevo's type) is also more expensive than HEFA, the most common type of SAF (see above). Bulls argue HEFA will face future feedstock supply constraints (e.g. used oil), hence the need for ATJ.
The EU has mandated 6% SAF use by 2030, but even when the rule is implemented, current and incoming HEFA production will more than cover demand.
In the US, the DOE believes that HEFA won't cover SAF needs in 2030. But the DOE has assumed SAF would account for 12% (3b gal) of all fuel usage (25b gal) even though SAF adoption will be voluntary in the US, while Europe's 6% is mandatory.
Hard to believe that US airlines would voluntarily use twice more SAF than their European peers while airline margins are notoriously thin. Assuming 6% usage, in line with the EU in 2030, we found that expected US HEFA capacity (1.7b) will cover SAF needs (1.5b gal).
Worse, the electrification of vehicles will reduce the usage of renewable diesel, which shares the same feedstock as HEFA. This would release HEFA supply in favour of SAF. Another issue is that the EU bans crop-based biofuels like corn. Corn is Gevo's primary feedstock.
The track record of operators is crucial for a project as large as Gevo's ATJ plant. Gevo is known to have a history of under-delivering on promises. In 2019 for example, management unveiled plans to achieve $63-$77m of revenue in 2021. Actual revenue for the year was $0.5m.
Since 2013, the company has burnt through $678m of cash, and raised $887m in common equity. Share count has grown about 16x since 2019. Still, top managers received very attractive compensation packages despite this poor performance.
We believe the shifting political landscape and the challenging economics of ATJ make Gevo's renewable project highly speculative and prone to failure.

GEVO

Iceberg Research Posts On X "We are short Gevo Inc ($GEVO). The change in the US administration is the obvious threat but problems run deeper, in particular the competitiveness of technology. A lot of room to fall further."

HC Wainwright &amp; Co. analyst Yi Chen reiterates Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) with a Buy and maintains $5 price target.

Reiteration

BRNS

HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $5 Price Target

Barclays analyst Brandt Montour maintains Marriott Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) with a Equal-Weight and raises the price target from $74 to $97.

Barclays Maintains Equal-Weight on Marriott Vacations, Raises Price Target to $97

In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on scPharmaceuticals (SCPH – Research Report), with a price target of $2...

TD Cowen Sticks to Its Buy Rating for scPharmaceuticals (SCPH)

Leerink Partners analyst Roanna Ruiz maintained a Buy rating on scPharmaceuticals (SCPH – Research Report) yesterday and set a price target of $20....

Buy Rating Affirmed for scPharmaceuticals Amidst FDA Approval and Strong Financial Performance

scPharmaceuticals GAAP EPS of -$0.44 misses by $0.02, revenue of $8.05M beats by $0.08M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
scPharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/scph-stock-quote/">SCPH</a>) just reported results for the second quarter of 2024.<ul><li>scPharmaceuticals reported earnings per share of -44 cents. This was below the analyst estimate for EPS of -40 cents.</li><li>The company reported revenue of $8.05 million.</li><li>This was 0.44% worse than the analyst estimate for revenue of $8.09 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/scph-stock-earnings-scpharmaceuticals-for-q2-of-2024/">SCPH Stock Earnings: scPharmaceuticals Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SCPH Stock Earnings: scPharmaceuticals Misses EPS, Misses Revenue for Q2 2024

scPharmaceuticals Inc. (SCPH) Q2 2024 Earnings Call Transcript

Maxim Group analyst Naz Rahman reiterated a Buy rating on scPharmaceuticals (SCPH – Research Report) yesterday and set a price target of $20.00. Na...

Buy Rating Affirmed: scPharmaceuticals's Revenue Surge and Product Development Promise

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kronos Bio (KRON – Research Report), Spruce Biosciences (SPRB – R...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Kronos Bio (KRON), Spruce Biosciences (SPRB) and scPharmaceuticals (SCPH)

In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on scPharmaceuticals (SCPH – Research Report). The company's ...

Craig-Hallum Remains a Buy on scPharmaceuticals (SCPH)

Maxim Group analyst Naz Rahman has reiterated their bullish stance on SCPH stock, giving a Buy rating yesterday. Naz Rahman has given his Buy ratin...

Strategic Buy Rating for scPharmaceuticals: Furoscix's Potential in CKD Market

Roanna Ruiz, an analyst from Leerink Partners, maintained the Buy rating on scPharmaceuticals (SCPH – Research Report). The associated price target...

Strategic Growth and Market Expansion Opportunities Drive Buy Rating for scPharmaceuticals

KRON

SCPH

SPRB

Health Care

Press Releases

scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic Kidney Disease

Comments

scPharmaceuticals

Notizie

Ultime notizie per scPharmaceuticals (NASDAQ:SCPH) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO